Skip to main content
Swing Capital

Supriya Lifescience Ltd

NSE: SUPRIYA BSE: 543434Pharma

Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]

₹681
52W: ₹546 — ₹832
PE 29.5 · Book ₹134 · +408% vs book
Market Cap₹5,482 Cr
Stock P/E29.5Price to Earnings
ROCE27.5%Return on Capital
ROE20.8%Return on Equity
Div. Yield0.15%Face Value ₹2

Strengths

  • +Company is almost debt free.

Shareholding Pattern

Promoters68.3%
FIIs5.16%
DIIs5.7%
Public20.83%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters68.3%68.3%68.3%68.3%68.3%68.3%68.3%68.3%
FIIs4.95%6.03%▲1.16.52%▲0.57.19%▲0.76.78%▼0.45.46%▼1.35.19%▼0.35.16%▼0.0
DIIs5.48%5.45%▼0.04.93%▼0.54.26%▼0.74.86%▲0.65.22%▲0.45%▼0.25.7%▲0.7
Public21.27%20.22%▼1.120.25%▲0.020.25%20.08%▼0.221.02%▲0.921.49%▲0.520.83%▼0.7

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales140140158161166186184145200206
Expenses108991039810112011793127134
Operating Profit32415663656668527372
OPM %23%30%35%39%39%36%37%36%36%35%
Net Profit24303745464750355050
EPS ₹2.973.74.595.555.735.816.264.326.276.17

AI Insights

Revenue Trend

TTM revenue at ₹735Cr, up 5.6% YoY. OPM at 36%.

Debt Position

Borrowings at ₹5Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.

Capex Cycle

CWIP at ₹172Cr (38% of fixed assets). Significant capex underway — growth runway building.

Institutional Flow

DIIs: 5.7% (-1.84pp change). FIIs: 5.16% (-0.57pp change). Promoters hold 68.3%.

Margin & Efficiency

ROCE improving from 0% (Mar 2017) to 27% (Mar 2025). Working capital days: 144.

Valuation

PE 29.5x with 27.5% ROCE. Price is 408% above book value of ₹134. Dividend yield: 0.15%.

Recent Announcements